SecBot SecBot
6-K ·Filed Nov 12, 2026

GSK

GSK plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 13h ago SEC0001654954-26-009712
Notable filing: 6-K
Actionable Insight • Neutral

Routine share plan transactions have no material impact on GSK's stock. Monitor upcoming quarterly results for fundamental drivers.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$50.64
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.38%
T+1 · $50.45
Vs SPY
−0.01%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $50.64entry
  2. T+1 · 4d ago −0.38%α −0.01% · $50.45
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a Form 6-K reporting routine share acquisitions by multiple PDMRs (directors and senior executives) under the company's Share Reward Plan on November 10, 2026. The transactions are small in value and represent standard equity plan participation, not open-market purchases. No financial results or material corporate events are disclosed.

Key Facts

  • Eight PDMRs and one PCA acquired ordinary shares under GSK's Share Reward Plan on November 10, 2026
  • Each PDMR (except Victoria Whyte) acquired 12 ordinary shares at GBP 19.3453 per share; Victoria Whyte acquired 14 shares
  • Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 in her Executive Supplemental Savings Plan account on November 9, 2026
  • Total value of all ordinary share acquisitions is approximately GBP 2,088 (about $2,600)
  • All transactions were pre-scheduled plan acquisitions, not discretionary open-market purchases

Financial Impact

Approximately GBP 2,088 total value of ordinary share acquisitions; negligible relative to GSK's $103.6B market cap

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-009712
Document: 0001654954-26-009712-index-headers.html0001654954-26-009712
Document: 0001654954-26-009712-index.html0001654954-26-009712
Document: 0001654954-26-009712.txt0001654954-26-009712
Earnings Context (Synthetic; results releases only)0001654954-26-009712

Track record

64 reports on GSK

Performance horizon

9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Viewing Entry $50.64 Now $50.41 −0.45% settles Dec 11
  3. Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
  4. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
  5. Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  7. Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  8. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  9. Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  10. Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
Showing 10 of 64

US Market Status

Market Closed · Opens in 9h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026